Opinions can differ on this matter, but it's not clear to me that market prices for isotopes have in fact been at a level that would be fully compensatory for AECL. Many factors go into the determination of international market prices; we do not have control over the pricing of our product in that marketplace, so I would take some issue with the notion that isotopes are a highly profitable business for us. We receive a revenue share, but we incur significant costs, and at this point in time this business line is one in which our cash out has substantially exceeded our cash in.
On August 21st, 2009. See this statement in context.